Drug intelligence / Profile preview

ASC303

Development stage: Preclinical
Lead developer: Ascle Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

ASC303 is an allogeneic natural killer (NK) cell therapy being developed by Ascle Therapeutics for the treatment of apoplexy (stroke). It is part of the company's ASC3xx series, which focuses on neurological conditions using an allogeneic NK cell platform. The therapy is designed to leverage the immunomodulatory and potentially neuroprotective properties of NK cells to mitigate the damage caused by stroke events. While the specific molecular targets have not been disclosed, the treatment aims to address neuroinflammation and promote tissue repair. As of early 2024, ASC303 is in the preclinical stage of development.

Beyond the preview

Go deeper on ASC303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC303.

Explore the full profile